Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment

BACKGROUND: Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20–30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy. METHODS: The...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Transl Med
Autors principals: Botticelli, Andrea, Vernocchi, Pamela, Marini, Federico, Quagliariello, Andrea, Cerbelli, Bruna, Reddel, Sofia, Del Chierico, Federica, Di Pietro, Francesca, Giusti, Raffaele, Tomassini, Alberta, Giampaoli, Ottavia, Miccheli, Alfredo, Zizzari, Ilaria Grazia, Nuti, Marianna, Putignani, Lorenza, Marchetti, Paolo
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6998840/
https://ncbi.nlm.nih.gov/pubmed/32014010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02231-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars